Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the Phase 1 portion of this study is to determine the MTD of the combination therapy of pemetrexed and carboplatin when administered to patients with platinum-sensitive recurrent ovarian cancer. Subsequent references to the study population (“patients with ovarian cancer”) will include the subpopulation of patients with primary peritoneal cancer. The primary objective of the Phase 2 portion of this study is to determine the overall tumor response rate of the combination therapy of pemetrexed and carboplatin when administered to patients with platinum-sensitive recurrent ovarian cancer. Subsequent references to the study population (“patients with ovarian cancer”) will include the subpopulation of patients with primary peritoneal cancer.
Critère d'inclusion
- platinum sensitive recurrent ovarian or primary peritoneal cancer